NASDAQ:SLP Simulations Plus Q4 2026 Earnings Date & Estimates $18.50 0.00 (0.00%) As of 11/6/2026 Simulations Plus is estimated to report Q4 2026 earnings on Monday, December 7, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ4 2026Announcement DateDecember 7, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Simulations Plus in Q4 2026Simulations Plus is expected to post earnings of $0.14 per share on revenue of $19.18 million. In the same quarter a year earlier Simulations Plus reported $0.10 per share on revenue of $17.46 million. Simulations Plus last reported on July 9, 2026, posting $0.30 per share and beating the $0.2325 consensus estimate. Simulations Plus has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.14Expected Revenue$19.18 millionPrior-Year EPS$0.10Prior-Year Revenue$17.46 millionExpected EPS Growth+40.0%Expected Revenue Growth+9.9%Recent Track RecordLast ReportedQ3 2026Last Quarter EPS$0.30 (Beat by +$0.0675)Last Quarter Revenue$21.89 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q4 2026 CallEarnings HistoryCompany ProfileQ3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Simulations Plus Q4 2026 Earnings FAQ When does Simulations Plus report Q4 2026 earnings? Simulations Plus (NASDAQ:SLP) is estimated to report Q4 2026 earnings on Monday, December 7, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Simulations Plus' Q4 2026 earnings call? Simulations Plus' Q4 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 3:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Simulations Plus? Analysts expect Simulations Plus to post earnings of $0.14 per share for Q4 2026. How much revenue is Simulations Plus expected to report? The consensus revenue estimate for Simulations Plus is $19.18 million for Q4 2026. Simulations Plus Earnings HeadlinesSimulations Plus, Inc. (NASDAQ:SLP) Stock Has Average Price Target of $17.25 According to BrokeragesNovember 14 at 2:15 AM | americanbankingnews.comJohnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting DisclosuresOctober 22, 2026 | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 14 at 1:00 AM | Weiss Ratings (Ad)Simulations Plus, Inc. Announces Funded Partnership With Global Pharmaceutical Company To Advance AI-Enabled QSP Model Development With TurinOctober 9, 2026 | marketscreener.comMAltaris Completes Acquisition of Simulations PlusOctober 7, 2026 | finance.yahoo.comSimulations Plus, Inc.(NasdaqGS:SLP) dropped from Russell 2000 Growth BenchmarkOctober 6, 2026 | marketscreener.comMSee More Simulations Plus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Simulations Plus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Simulations Plus and other key companies, straight to your email. Email Address About Simulations PlusSimulations Plus (NASDAQ:SLP) develops software and provides consulting services for the pharmaceutical and biotechnology industries. Its tools help researchers model how drugs behave in the body, assess drug properties, and support decisions during drug discovery and development. The company’s products include GastroPlus for physiologically based pharmacokinetic modeling and simulation, ADMET Predictor for estimating absorption, distribution, metabolism, excretion and toxicity properties, and MonolixSuite for pharmacometrics and quantitative pharmacology. Simulations Plus also offers consulting in areas such as drug development modeling, regulatory strategy and data analysis. Founded in 1996, Simulations Plus serves pharmaceutical and biotechnology companies, academic researchers and regulatory organizations in the United States and internationally. Its software and services are used across multiple stages of drug development, from early research through clinical development.View Simulations Plus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
